Results 131 to 140 of about 29,100 (168)

Trends in Antipsychotic Drug Use in the United States, 2000-2016. [PDF]

Pharmacy (Basel)
Haddad N, Farhat N, Go J, Chen Y, Gravel CA, Momoli F, Mattison DR, McNair D, Alami A, Krewski D.   +9 more
europepmc   +1 more source

Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to <i>in ovo</i> investigation. [PDF]

Front Oncol
Jain A, Motatis AKB, Dharmashekar C, Shreevatsa B, Vs S, Srinivas M, Srinivasa SM, P A, Prasad MNN, Rosell R, Codony-Servat J, Rangappa S, Iqbal M, Abass KS, Amachawadi RG, Stupin V, Kollur SP, Shivamallu C, Silina E.   +18 more
europepmc   +1 more source

Unexpected resolution of clozapine-induced obsessive-compulsive symptoms with cariprazine augmentation: a case report. [PDF]

BMC Psychiatry
Rammouz I, El Oumary O, Hamri S, Akebour K, Mouhadi K, Doufik J, Boujraf S.   +6 more
europepmc   +1 more source

Population Pharmacokinetic-Based Strategies for Switching Patients with Schizophrenia Between Long-Acting Injectable Formulations of Risperidone: R064766 or RBP-7000 to TV-46000. [PDF]

Neurol Ther
Perlstein I, Meyer J, Kumar S, Yue Z, Ivaturi V, Franzenburg KR, Suett M, Hansen R, Merenlender Wagner A, Phatak A, Singh R.   +10 more
europepmc   +1 more source

Comments on "Ketamine's double-edged sword: Therapeutic benefits and adverse events in adolescent treatment-resistant obsessive compulsive disorder (OCD)-A case series". [PDF]

Indian J Psychiatry
Birdi R, Achary U, Bakam A.
europepmc   +1 more source

Correction: Antipsychotic‑Related Prolactin Changes: A Systematic Review and Dose-Response Meta‑analysis. [PDF]

CNS Drugs
Lin X, Siafis S, Tian J, Wu H, Qin M, Correll CU, Schneider-Thoma J, Leucht S.   +7 more
europepmc   +1 more source

Real-world pharmacovigilance of risperidone: Analysis based on FAERS reports from physicians and pharmacists. [PDF]

PLoS One
Hao G, Jia Z, Zan Y, Lv X, Li N, Zhou J.
europepmc   +1 more source